LAG3 and colorectal carcinoma: As such, there is strong interest in combining PD-(L)1 inhibitors with other treatment agents, including LAG-3 inhibitors, chemotherapy, and biological agents, to improve clinical responses in advanced solid tumour types, including colorectal cancer (CRC) [4, 8, 9].